ORNBV.HE

Orion Oyj [ORNBV.HE] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

ORNBV.HE Stock Summary

EPS has been increasing for the past 3 quarters (Quarter statements)

Earnings are expected to fall -100% next year

Unstable dividend track record

Profit margins (0.15%) are lower than the previous year (0.18%)

ORNBV.HE has less than 1 year of cash runway

An RSI reading of 30 or below indicates an oversold or undervalued condition.

Top 10 Correlated ETFs

ORNBV.HE

Top 10 Correlated Stocks

ORNBV.HE

In the News

ORNBV.HE Financial details

Company Rating

Strong Buy

Market Cap

4.66B

Income

216.8M

Revenue

1.19B

Book val./share

6.34

Cash/share

0.76

Dividend

1.6

Dividend %

3.84%

Employees

3.63K

Optionable

Shortable

Yes

Earnings

25 Apr 2024

P/E

33.53

Forward P/E

PEG

-8.88

P/S

4.98

P/B

6.91

P/C

42.24

P/FCF

-128.23

Quick Ratio

0.05

Current Ratio

3.1

Debt / Equity

0.22

LT Debt / Equity

0.19

EPS (TTM)

1.55

EPS next Y

EPS next Q

EPS this Y

-37.75%

EPS next Y

EPS next 5Y

EPS last 5Y

1.62%

Revenue last 5Y

2.51%

Revenue Q/Q

6.64%

EPS Q/Q

22.73%

SMA20

-7.95%

SMA50

-23.47%

SMA100

-12.44%

Inst Own

Inst Trans

ROA

13%

ROE

21%

ROC

0.19%

Gross Margin

55%

Oper. Margin

19%

Profit Margin

15%

Payout

130%

Shs Outstand

Shs Float

Target Price

52W Range

32.61-47.31

52W High

-31.7%

52W Low

+0.31%

RSI

23.9

Rel Volume

0.03

Avg Volume

252.64K

Volume

8.3K

Perf Week

-1.8%

Perf Month

-9.88%

Perf Quarter

-11.91%

Perf Half Y

-16.84%

Beta

0.348

Volatility

0.38%, 1.31%

Prev Close

-0.53%

Price

32.1

Change

-0.77%

ORNBV.HE Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	7.48	7.67	7.41	9.54	8.48
Net income per share	1.43	1.57	1.38	2.49	1.54
Operating cash flow per share	1.93	2.13	1.53	3.09	0.85
Free cash flow per share	1.67	1.84	0.93	2.57	0.02
Cash per share	1.06	2.09	1.43	2.36	0.76
Book value per share	5.54	5.2	5.32	6.46	6.34
Tangible book value per share	5.18	4.9	4.83	5.1	4.92
Share holders equity per share	5.54	5.2	5.32	6.46	6.34
Interest debt per share	0.09	0.78	0.78	1.53	1.45
Market cap	5.8B	5.27B	5.13B	7.2B	5.51B
Enterprise value	5.7B	5.09B	5.02B	7.08B	5.6B
P/E ratio	28.95	23.98	26.48	20.6	25.42
Price to sales ratio	5.52	4.89	4.93	5.37	4.63
POCF ratio	21.42	17.63	23.8	16.57	46.31
PFCF ratio	24.73	20.41	39.27	19.93	2.5K
P/B Ratio	7.44	7.21	6.86	7.93	6.19
PTB ratio	7.44	7.21	6.86	7.93	6.19
EV to sales	5.42	4.72	4.83	5.28	4.71
Enterprise value over EBITDA	18.44	15.17	17.62	14.48	19.82
EV to operating cash flow	21.04	17.01	23.29	16.3	47.09
EV to free cash flow	24.29	19.69	38.44	19.6	2.55K
Earnings yield	0.03	0.04	0.04	0.05	0.04
Free cash flow yield	0.04	0.05	0.03	0.05	0
Debt to equity	0.01	0.15	0.15	0.24	0.22
Debt to assets	0.01	0.1	0.1	0.14	0.14
Net debt to EBITDA	-0.34	-0.55	-0.38	-0.24	0.33
Current ratio	3.2	3.47	3.3	3.19	3.12
Interest coverage	109.91	311.22	243.3	293.07	77.1
Income quality	1.07	1.07	0.89	0.99	0.55
Dividend Yield	0.04	0.04	0.04	0.03	0.04
Payout ratio	1.05	0.96	1.09	0.6	1.04
Sales general and administrative to revenue	0.05	0.05	0.05	0.05	0.06
Research and developement to revenue	0.11	0.11	0.11	0.1	0.11
Intangibles to total assets	0.05	0.04	0.06	0.13	0.14
Capex to operating cash flow	-0.13	-0.14	-0.39	-0.17	-0.98
Capex to revenue	-0.03	-0.04	-0.08	-0.05	-0.1
Capex to depreciation	-0.65	-0.72	-1.86	-1.54	-2.27
Stock based compensation to revenue	0.01	0.01	0.01	0.01	0
Graham number	13.34	13.54	12.85	19.02	14.85
ROIC	0.25	0.26	0.22	0.31	0.17
Return on tangible assets	0.2	0.21	0.19	0.27	0.18
Graham Net	1.21	1.3	0.85	0.48	0.05
Working capital	412.5M	529.6M	481M	603.1M	560.5M
Tangible asset value	728.3M	688.2M	678.9M	717.2M	689.9M
Net current asset value	343.7M	359.3M	324.1M	283.1M	276.7M
Invested capital	0.01	0.15	0.15	0.24	0.22
Average receivables	108.5M	204.1M	197.1M	216.75M	293.5M
Average payables	76.95M	82.85M	88.15M	102M	108.35M
Average inventory	226.2M	244.2M	261.65M	290.4M	338.9M
Days sales outstanding	75.37	64.73	71.18	62.75	109.37
Days payables outstanding	69.05	74.11	73.08	84.92	70.2
Days of inventory on hand	201.29	220.62	216.31	234.28	248.55
Receivables turnover	4.84	5.64	5.13	5.82	3.34
Payables turnover	5.29	4.93	4.99	4.3	5.2
Inventory turnover	1.81	1.65	1.69	1.56	1.47
ROE	0.26	0.3	0.26	0.38	0.24
Capex per share	-0.26	-0.29	-0.6	-0.52	-0.83

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	2.1	1.98	2.06	2.15	2.29
Net income per share	0.23	0.31	0.26	0.44	0.54
Operating cash flow per share	0.04	0.03	0.24	0.24	0.35
Free cash flow per share	-0.15	-0.36	0.11	0.07	0.19
Cash per share	2.37	0.71	0.13	0.08	0.76
Book value per share	6.48	5.19	5.47	5.99	6.34
Tangible book value per share	5.12	3.83	4.11	4.59	4.92
Share holders equity per share	6.48	5.19	5.47	5.99	6.34
Interest debt per share	1.53	1.5	1.48	1.44	1.43
Market cap	7.18B	5.78B	5.34B	5.22B	5.51B
Enterprise value	7.07B	5.89B	5.47B	5.35B	5.6B
P/E ratio	56.83	32.97	36.65	21.27	18.32
Price to sales ratio	24.39	20.78	18.43	17.35	17.16
POCF ratio	1.31K	1.44K	160.73	158.3	112.94
PFCF ratio	-345.38	-116	339.88	538.54	206.43
P/B Ratio	7.91	7.94	6.95	6.22	6.19
PTB ratio	7.91	7.94	6.95	6.22	6.19
EV to sales	23.98	21.18	18.89	17.76	17.46
Enterprise value over EBITDA	164.69	106.09	117.35	66.75	79.84
EV to operating cash flow	1.28K	1.47K	164.71	162.01	114.85
EV to free cash flow	-339.68	-118.23	348.3	551.17	209.92
Earnings yield	0	0.01	0.01	0.01	0.01
Free cash flow yield	0	-0.01	0	0	0
Debt to equity	0.24	0.29	0.27	0.24	0.22
Debt to assets	0.14	0.16	0.16	0.15	0.14
Net debt to EBITDA	-2.76	2	2.84	1.53	1.33
Current ratio	3.19	2.63	2.89	3.1	3.12
Interest coverage	135.67	138.75	66.43	53.33	114.2
Income quality	0.14	0.07	0.72	0.42	0.65
Dividend Yield	0	0.03	0.01	0	0
Payout ratio	0	4.19	1.12	0.01	0
Sales general and administrative to revenue	0.06	0.06	0.07	0.05	0.06
Research and developement to revenue	0.13	0.11	0.11	0.09	0.11
Intangibles to total assets	0.13	0.15	0.15	0.14	0.14
Capex to operating cash flow	-4.78	-13.45	-0.53	-0.71	-0.45
Capex to revenue	-0.09	-0.19	-0.06	-0.08	-0.07
Capex to depreciation	-2.1	-4.41	-1.38	-1.73	-1.69
Stock based compensation to revenue	0.05	0	0	0	0
Graham number	5.73	6.04	5.65	7.68	8.74
ROIC	0.03	0.05	0.04	0.06	0.04
Return on tangible assets	0.02	0.04	0.03	0.05	0.06
Graham Net	0.48	-0.87	-1.13	-0.94	0.05
Working capital	603.1M	412.4M	441.7M	480.7M	560.5M
Tangible asset value	717.2M	537.5M	577M	644.4M	689.9M
Net current asset value	283.1M	100.6M	135.5M	178.1M	276.7M
Invested capital	0.24	0.29	0.27	0.24	0.22
Average receivables	201.25M	233.75M	243.45M	268.55M	321.85M
Average payables	99.65M	96.4M	86.45M	88.2M	92.1M
Average inventory	312.35M	321.85M	339.5M	347.8M	353.45M
Days sales outstanding	70.42	76.73	77.69	85.85	99.92
Days payables outstanding	73.91	57.93	62.54	56.79	63.8
Days of inventory on hand	203.91	242.44	232.21	239.01	225.9
Receivables turnover	1.28	1.17	1.16	1.05	0.9
Payables turnover	1.22	1.55	1.44	1.58	1.41
Inventory turnover	0.44	0.37	0.39	0.38	0.4
ROE	0.03	0.06	0.05	0.07	0.08
Capex per share	-0.19	-0.38	-0.12	-0.17	-0.16

ORNBV.HE Dividend History

ORNBV.HE Frequently Asked Questions

What is Orion Oyj stock symbol ?

Orion Oyj is a FI stock and trading under the symbol ORNBV.HE

What is Orion Oyj stock quote today ?

Orion Oyj stock price is $32.1 today.

Is Orion Oyj stock public?

Yes, Orion Oyj is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 252.64K
Market Capitalization 4.66B
Employee 3.63K
CEO Dr. Liisa Hurme
Headquarters Espoo,FI
IPO Date 2004-10-07
Website https://www.orion.fi

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. The company also offers veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; and APIs for generic and proprietary drugs, as well as provides contract manufacturing services. In addition, it markets and sells veterinary drugs manufactured by other international companies. The company serves various healthcare service providers and professionals, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories, as well as consumers with pets. Orion Oyj has partnership with Propeller Health to connect the Easyhaler(R) product portfolio for the treatment of asthma and COPD; and a research collaboration and license agreement with Alligator Bioscience AB (publ) to discover and develop new bispecific antibody cancer therapeutics. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.